Rock Springs Capital Management LP Has $19.73 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Rock Springs Capital Management LP raised its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 117.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 767,522 shares of the company's stock after acquiring an additional 414,203 shares during the period. Rock Springs Capital Management LP owned about 0.83% of NewAmsterdam Pharma worth $19,725,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. National Bank of Canada FI acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $80,000. KLP Kapitalforvaltning AS bought a new stake in NewAmsterdam Pharma in the 4th quarter valued at $154,000. Barclays PLC increased its holdings in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at about $224,000. 89.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James N. Topper purchased 1,135 shares of the stock in a transaction dated Wednesday, March 26th. The shares were bought at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the acquisition, the director now directly owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. This represents a 0.04 % increase in their position. The disclosure for this purchase can be found here. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Stock Up 0.3 %

Shares of NewAmsterdam Pharma stock traded up $0.05 during trading on Friday, reaching $17.52. The company's stock had a trading volume of 345,323 shares, compared to its average volume of 592,501. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $27.29. The firm has a market cap of $1.92 billion, a PE ratio of -6.74 and a beta of -0.01. The business's 50-day moving average price is $19.61 and its 200-day moving average price is $21.19.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million. Equities analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Scotiabank lifted their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $42.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.